Ypsomed Holding AG (YPHDF)

OTCMKTS · Delayed Price · Currency is USD
354.92
-12.98 (-3.53%)
At close: Apr 6, 2026
Market Cap5.29B -3.0%
Revenue (ttm)987.67M +27.6%
Net Income243.29M +160.8%
EPS17.82 +160.7%
Shares Outn/a
PE Ratio21.73
Forward PE23.78
Dividendn/a
Ex-Dividend Daten/a
Volume3
Average Volume63
Open354.92
Previous Close367.90
Day's Range354.92 - 354.92
52-Week Range354.92 - 535.75
Beta0.74
RSI50.24
Earnings DateMay 20, 2026

About Ypsomed Holding AG

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insu... [Read more]

Sector Healthcare
Founded 1984
Employees 2,000
Stock Exchange OTCMKTS
Ticker Symbol YPHDF

Financial Performance

In fiscal year 2025, Ypsomed Holding AG's revenue was 748.87 million, an increase of 36.54% compared to the previous year's 548.46 million. Earnings were 87.50 million, an increase of 11.66%.

Financial numbers in CHF Financial Statements

News

Ypsomed Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Management outlined a strategic shift to a pure-play injection device business, driven by strong growth in injectables, biosimilars, and GLP-1 therapies. Financial targets include doubling sales by 2030, maintaining high margins, and expanding global production, with risks mainly in execution and market volatility.

4 months ago - Transcripts

Ypsomed Holding AG Transcript: H1 25/26

Strong H1 results driven by 21% core sales growth, 32.4% EBIT margin, and strategic focus on B2B injection devices. Guidance for 20% annual sales growth and >30% EBIT margin is confirmed, with major capacity expansion and innovation underway.

6 months ago - Transcripts

Ypsomed Holding AG Transcript: H2 24/25

Exceeded sales and profitability targets with 37% revenue growth, driven by delivery systems and global capacity expansion. Divestment of diabetes care and strong project pipeline position the company for 20% growth and higher EBIT next year.

1 year ago - Transcripts